跳至主要内容
临床试验/CTRI/2022/09/045268
CTRI/2022/09/045268尚未招募2/3 期

Randomized open controlled clinical trial of nagaradi churna on kaphaja pandu w s r to anemia

Dr Diksha Sonwane1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2022年12月9日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
110
试验地点
1
主要终点
Scales of following symptoms

研究概览

简要总结

As iron deficiency anemia is the most common type of the anemia

worldwide. In conventional medicine various forms of treatment are used. There are some adverse effects of allopathic treatment. As the anemia is very common prevalent disease in the society, so to get better alternative, an ayurvedic herbo-mineral medicine, Nagaradi Churna will be subjected to a clinical trial in the anemic patients.

The present study was carried out to carry the efficiency of an

Ayurveda herbomineral compound “NAGARADI CHURNAâ€

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
16.00 Year(s) 至 60.00 Year(s)(—)

入选标准

  • 1.Gender-Patients of any gender will be included.
  • 2.Age-16 yrs to 60 yrs 3.Patients those having Lakshanas of kaphaja Pandu.
  • 4.Hb% ranges above 7gm/dL to 10gm/dL.
  • 5.Patient who shows Panduta,Guruta,Tandra, shithilata, Alasya ,Aruchi, shwas will be included for study.

排除标准

  • 1.Pregnant women, Lactating mothers.
  • 2.Anemia associated with other known history of diseases like Nephrotic Syndrome, Liver Cirrhosis, Ascites, Congestive Cardiac Failure, Acute Coronary Syndromes, Leprosy, Auto- Immune Disorders etc.
  • 3.Patients having known history of Chronic Blood loss conditions such as Malena, Haemetemesis, Haemorrhagic Piles, Menorrhagia, Metrorrhagia, etc.

结局指标

主要结局

Scales of following symptoms

时间窗: 2 weeks

1)Panduta

时间窗: 2 weeks

3)Tandra

时间窗: 2 weeks

5)Shwas

时间窗: 2 weeks

6)Aruchi

时间窗: 2 weeks

7)Shithilata

时间窗: 2 weeks

2)Guruta

时间窗: 2 weeks

4)Alasya

时间窗: 2 weeks

次要结局

  • Increase hemoglobin(90 days)

研究者

发起方
Dr Diksha Sonwane
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验